However, blocking mTOR activity with rapamycin (the prototype mTOR inhibitor) or rapamycin analogs inadvertently activates the Akt-signaling pathway [9] through an IGF-1R-dependent mechanism [10], which mitigates the anti-tumor effects of the mTOR inhibitors. This evidence concerns the gene MTOR and neoplasm.